All eyes are on the preliminary data Moderna is preparing to submit to the monitoring board on its vaccine candidate's effectiveness, which works on technology similar to Pfizer's.
The candidate is a so-called messenger RNA vaccine, based on technology similar to that used by one of the fastest-moving vaccine developers, Moderna Inc.
Moderna decided to make the declaration because investors had started noticing that the company has patents that might apply to other Covid vaccines, says its president.
The vaccine, called mRNA-1273, is being developed by Moderna with the US govt's National Institutes of Health. The small study involved 40 adults aged over 56.
The results from Moderna’s early-stage trial, which include data from 20 participants, are important because older adults often don’t respond as well to vaccines as younger adults.
In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.
Using this technology, IDF carried out fully robotic combat missions, drastically reducing risk to Israeli troops. The robotic combat task force also enhanced situational awareness.
While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.
COMMENTS